Claudia Hirawat is a biotechnology executive experienced in management, corporate and business development, patient advocacy and other corporate functions. Ms. Hirawat serves as Chair of EURORDIS International Circle of Ambassadors (EURORDIS is a non-governmental patient-driven alliance of patient organisations representing 30 million people affected by rare diseases throughout Europe, 692 rare disease patient organisations in 63 countries) and as a business advisor to biotechnology companies and non-profit groups. Ms. Hirawat retired from PTC Therapeutics, Inc. in January 2016, after serving as the Company’s President since 2012. As President, in partnership with the CEO and the senior management team, Ms. Hirawat led the company through multiple rounds of financing including a large mezzanine round and a successful Initial Public Offering (IPO) as well as the conditional approval of the Company's first product: Translarna, for the treatment of Duchenne muscular dystrophy. Ms. Hirawat was pivotal in supporting the development of the commercial organization to launch Translarna while also overseeing business development, alliance management and other functions. Prior to being President of PTC, Ms. Hirawat served as Senior Vice President of Corporate Development and was responsible for business and corporate development - spearheading PTC’s multiple collaborations as the Company's lead negotiator. Ms. Hirawat joined PTC in 2000 and played a key role in building the Company - always directly involved in fundraising, operational directives, public and investor relations, patient and professional advocacy and commercial development. Prior to PTC, Ms. Hirawat served as a Vice President at LedbetterStevens, a management consulting and senior-level retained search firm in New York focused exclusively in the biopharmaceutical area. Ms. Hirawat was at LedbetterStevens for five years and had responsibilities for projects for a variety of clients including: Pfizer, Pharmacia, Bristol Myers Squibb Co., Celera Genomics, Coelacanth Corp., SpotFire, IBM Consulting/The Wilkerson Group and The Boston Consulting Group. Ms Hirawat is passionate about the rights and the role of the patient at every stage of drug discovery, development, commercialization and delivery of care. Her philanthropic efforts are focused on rare disorders, oncology, mental health and patient and human rights @ClaudiaHirawat.